Literature DB >> 2515219

Effect of the potentiation of cholinergic activity on the variability in individual GH response to GH-releasing hormone.

E Mazza1, E Ghigo, S Goffi, M Procopio, E Imperiale, E Arvat, J Bellone, M F Boghen, E E Müller, F Camanni.   

Abstract

In man the GH response to GHRH is highly variable and some normal subjects may be completely unresponsive to the neuropeptide. On the other hand, the potentiation of cholinergic activity by pyridostigmine (PD), a cholinesterase inhibitor, increases the GH response to GHRH, probably by inhibiting somatostatin release. The aim of this study was to assess the existence of intraindividual variability in the GH response to GHRH and verify the effects of PD treatment on inter- and intraindividual variability. Twenty normal adults (17 M and 3 F) and 10 normal prepubertal children (9 M and 1 F) underwent 2-5 administrations of 1 micrograms/kg GHRH on different days. Seven adults and all children also underwent 1-5 other tests in which GHRH was preceded (60 min before) by oral PD (120 mg in adults and 60 mg in children). The GH responses to GHRH were highly variable, not only within subjects but also in the same subject on different occasions (peak range; adults: 0.4-49.0 ng/ml; children: 2.4-50.0 ng/ml). PD always markedly increased the GH response to GHRH, even unmasking this response in 3 adults and 4 children hyporesponsive to the neuropeptide alone. However, the variability in the GH response was still present (adults: 27.2-108.5 ng/ml; children: 25.0-144.0 ng/ml), though reduced (adults: p = 0.0005; children: p = 0.0204). These data indicate that: i. A great inter- and intraindividual variability in the GH response to GHRH is present.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2515219     DOI: 10.1007/BF03350063

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  15 in total

1.  Pyridostigmine metabolism in man.

Authors:  S M Somani; J B Roberts; A Wilson
Journal:  Clin Pharmacol Ther       Date:  1972 May-Jun       Impact factor: 6.875

2.  Enhancement of cholinergic tone by pyridostigmine promotes both basal and growth hormone (GH)-releasing hormone-induced GH secretion in children of short stature.

Authors:  E Ghigo; E Mazza; E Imperiale; G Rizzi; L Benso; E E Müller; F Camanni; F Massara
Journal:  J Clin Endocrinol Metab       Date:  1987-09       Impact factor: 5.958

3.  Potentiation of cholinergic tone by pyridostigmine bromide re-instates and potentiates the growth hormone responsiveness to intermittent administration of growth hormone-releasing factor in man.

Authors:  F Massara; E Ghigo; P Molinatti; E Mazza; V Locatelli; E E Müller; F Camanni
Journal:  Acta Endocrinol (Copenh)       Date:  1986-09

4.  Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty.

Authors:  J M Tanner; R H Whitehouse
Journal:  Arch Dis Child       Date:  1976-03       Impact factor: 3.791

5.  Human pancreatic tumor growth hormone-releasing factor: dose-response relationships in normal man.

Authors:  M L Vance; J L Borges; D L Kaiser; W S Evans; R Furlanetto; J L Thominet; L A Frohman; A D Rogol; R M MacLeod; S Bloom
Journal:  J Clin Endocrinol Metab       Date:  1984-05       Impact factor: 5.958

6.  Effects of human pancreatic growth hormone-releasing factor-40 on serum growth hormone, prolactin, luteinizing hormone, follicle-stimulating hormone, and somatomedin-C concentrations in normal women throughout the menstrual cycle.

Authors:  W S Evans; J L Borges; M L Vance; D L Kaiser; A D Rogol; R Furlanetto; J Rivier; W Vale; M O Thorner
Journal:  J Clin Endocrinol Metab       Date:  1984-11       Impact factor: 5.958

7.  Human pancreatic growth-hormone-releasing factor selectively stimulates growth-hormone secretion in man.

Authors:  M O Thorner; J Rivier; J Spiess; J L Borges; M L Vance; S R Bloom; A D Rogol; M J Cronin; D L Kaiser; W S Evans; J D Webster; R M MacLeod; W Vale
Journal:  Lancet       Date:  1983-01-01       Impact factor: 79.321

8.  Dose-response relationships for the effects of growth hormone-releasing factor-(1-44)-NH2 in young adult men and women.

Authors:  M C Gelato; O H Pescovitz; F Cassorla; D L Loriaux; G R Merriam
Journal:  J Clin Endocrinol Metab       Date:  1984-08       Impact factor: 5.958

9.  Involvement of the somatostatin and cholinergic systems in the mechanism of growth hormone autofeedback regulation in the rat.

Authors:  A Torsello; G Panzeri; P Cermenati; M C Caroleo; E Ghigo; F Camanni; E E Müller; V Locatelli
Journal:  J Endocrinol       Date:  1988-05       Impact factor: 4.286

10.  Cholinergic agonist and antagonist drugs modulate the growth hormone response to growth hormone-releasing hormone in the rat: evidence for mediation by somatostatin.

Authors:  V Locatelli; A Torsello; M Redaelli; E Ghigo; F Massare; E E Müller
Journal:  J Endocrinol       Date:  1986-11       Impact factor: 4.286

View more
  7 in total

Review 1.  Growth hormone-releasing hormone and growth hormone secretagogue-receptor ligands: focus on reproductive system.

Authors:  E Arvat; L Gianotti; R Giordano; F Broglio; M Maccario; F Lanfranco; G Muccioli; M Papotti; A Graziani; E Ghigo; R Deghenghi
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

2.  IGF-I levels rise and GH responses to GHRH decrease during long-term prednisone treatment in man.

Authors:  M H Borges; A C Pinto; F B DiNinno; C Camacho-Hübner; A Grossman; C E Kater; A M Lengyel
Journal:  J Endocrinol Invest       Date:  1999-01       Impact factor: 4.256

3.  Somatostatinergic tone in children on chronic haemodialysis and after renal transplantation.

Authors:  M Cappa; P del Balzo; G Rizzoni; S Benedetti; P Borrelli
Journal:  Pediatr Nephrol       Date:  1991-07       Impact factor: 3.714

Review 4.  Growth hormone-releasing hormone combined with arginine or growth hormone secretagogues for the diagnosis of growth hormone deficiency in adults.

Authors:  E Ghigo; G Aimaretti; E Arvat; F Camanni
Journal:  Endocrine       Date:  2001-06       Impact factor: 3.633

Review 5.  Involvement of brain catecholamines and acetylcholine in growth hormone deficiency states. Pathophysiological, diagnostic and therapeutic implications.

Authors:  E E Müller; V Locatelli; E Ghigo; S G Cella; S Loche; C Pintor; F Camanni
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

6.  Variability in the growth hormone response to growth hormone-releasing hormone alone or combined with pyridostigmine in type 1 diabetic patients.

Authors:  A Giustina; C Bodini; S Bossoni; U Valentini; W B Wehrenberg
Journal:  J Endocrinol Invest       Date:  1993-09       Impact factor: 4.256

7.  Therapeutical doses of salbutamol inhibit the somatotropic responsiveness to growth hormone-releasing hormone in asthmatic children.

Authors:  E Ghigo; M R Valetto; L Gaggero; A Visca; F Valente; J Bellone; D Castello; F Camanni
Journal:  J Endocrinol Invest       Date:  1993-04       Impact factor: 4.256

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.